

S3 Table. Treatment-related AEs associated with permanent discontinuation of crizotinib

	Asian	Non-Asian	Overall population
PROFILE 1007	n=79	n=93	n=172
Any AE	9 (11.4)	2 (2.2)	11 (6.4)
Interstitial lung disease ^{a)}	4 (5.1)	0	4 (2.3)
Elevated transaminases ^{a)}	2 (2.5)	0	2 (1.2)
Arrhythmia	1 (1.3)	0	1 (0.6)
Hepatotoxicity ^{a)}	1 (1.3)	0	1 (0.6)
Neutropenia ^{a)}	1 (1.3)	0	1 (0.6)
Cytolytic hepatitis	0	1 (1.1)	1 (0.6)
Nausea	0	1 (1.1)	1 (0.6)
PROFILE 1014	n=77	n=94	n=171
Any AE	5 (6.5)	3 (3.2)	8 (4.7)
Interstitial lung disease ^{a)}	1 (1.3)	1 (1.1)	2 (1.2)
Elevated transaminases ^{a)}	2 (2.6)	0	2 (1.2)
Hepatotoxicity ^{a)}	1 (1.3)	1 (1.1)	2 (1.2)
Renal cyst ^{a)}	1 (1.3)	0	1 (0.6)
Nausea	0	1 (1.1)	1 (0.6)

Values are presented as number (%). AE, adverse event. ^{a)}This item comprised a cluster of AEs that may represent similar clinical symptoms or syndromes, listed in S4 Table.